Avidity Biosciences (RNA) Expected to Post Quarterly Earnings on Thursday

Avidity Biosciences (NASDAQ:RNA) is expected to issue its Q3 2026 resultson Thursday, November 12th. Analysts expect the company to announce earnings of ($0.8109) per share and revenue of $15.00 million for the quarter. Individuals can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Avidity Biosciences (NASDAQ:RNA) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($1.18) EPS for the quarter, beating the consensus estimate of ($1.42) by $0.24. The business had revenue of $3.00 million during the quarter, compared to analysts’ expectations of $0.67 million. On average, analysts expect Avidity Biosciences to post ($4.45) EPS for the current fiscal year and ($6.69) EPS for the next fiscal year.

Avidity Biosciences Trading Down 0.5%

NASDAQ RNA opened at $8.68 on Thursday. Avidity Biosciences has a 12 month low of $7.49 and a 12 month high of $16.77. The stock’s 50 day moving average is $9.47 and its 200 day moving average is $20.51. The stock has a market cap of $148.51 million and a PE ratio of -4.04.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Roth Capital initiated coverage on shares of Avidity Biosciences in a research note on Thursday, October 22nd. They issued a “buy” rating and a $15.00 price target on the stock. Weiss Ratings raised shares of Avidity Biosciences from a “sell (e-)” rating to a “sell (e)” rating in a research note on Monday, August 3rd. Finally, HC Wainwright dropped their price objective on shares of Avidity Biosciences from $25.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $40.80.

Avidity Biosciences Company Profile

Avidity Biosciences, Inc is a biotechnology company focused on developing RNA-based medicines for genetic diseases. The company’s approach is designed to address conditions that are difficult to treat with conventional oligonucleotide therapies, including diseases affecting skeletal muscle.

Avidity’s proprietary AOC (antibody oligonucleotide conjugate) platform combines monoclonal antibodies with oligonucleotide-based medicines. The antibody component is intended to help deliver the therapeutic payload to specific tissues, while the oligonucleotide component is designed to modify or regulate disease-related RNA.